AstraZeneca drops MASH drug over disappointing phase 2 data
AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a phase 2 study. The U.K.-based pharma had been evaluating the…
ESMO: AstraZeneca believes latest data ‘validate’ going it alone on next-gen ADCs
Europe’s leading cancer conference may be swimming in antibody-drug conjugate (ADC) data, but AstraZeneca remains convinced that its in-house pipeline sets the pharma apart. The U.K.-based drugmaker has earned its…
AstraZeneca pens fresh IBD collab with long-term AI partner Immunai worth $85M
AstraZeneca has returned to its longtime artificial intelligence partner Immunai with a new deal worth up to $85 million to advance a suitable target for a new inflammatory bowel disease…
AstraZeneca: Building a transparent pipeline from the ground up
Transparency is a word pharma companies often like to use, but, in practice, they rarely live up to the ideal. AstraZeneca is trying to be truly transparent with its new…
AstraZeneca pauses $271M expansion in UK—the latest Big Pharma to buck Britain
AstraZeneca has paused a 200 million pound sterling ($271 million) investment in its Cambridge, England, research site, a company spokesperson has confirmed to Fierce Biotech. The pharma’s pullback is the…